readi set v-go initi buy pt
valerita sell v-go novel basal-bolu insulin pump intend
type diabet patient popul like simpl design
technolog low cost demonstr clinic benefit patient
view valerita best shape sinc launch v-go
recent rais requir mani warrant capit need larg
met next two-thre year sell strategi gain
momentum less product salespeopl longer
compani gross margin expand near-term
salesforc expans yet vlrx share suffer last year
fund overhang cloud strong revenu result though signific
dilut stock warrant rais concern space
competit think y/i sale growth deserv higher multipl
current ntm revenu multipl
focu sale valerita doesnt face usual binari earli
stage catalyst like regulatori clearanc launch reimburs
valerita sell v-go year us broadli
reimburs pharmaci channel remov key risk
commonli seen micro-cap med-tech compani
compani concentr sell drive v-go adopt
current competit plenti data v-go type
pump market numer public
clinic benefit includ lower reduc insulin need
larg number warrant may dampen investor enthusiasm
declin vlrx stock price market volatil unfavor
time requir inclus mani warrantswith low exercis
pricesequival share anticip dilut may limit
near-term upsid stock though provid cash
valuat rate buy pt base
month revenu estim risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
believ valerita v-go devic provid patient type diabet
desir altern multipl daili inject mdi insulin
improv complianc clinic outcom unlik novel form
medic technolog see patient clinician disincent
associ use v-go cost per-day basi par mdi
devic broadli cover medicar commerci payor
technolog simpl use
impress demonstr benefit v-go use studi
shown v-go patient higher rate insulin therapi adher
report reduc level use less insulin overal think v-go
enjoy wider adopt among type patient popul believ type
patient often embarrass diseas born
type may benefit discreet pump one dose
insulin v-go without other nearbi know wherea imposs
pen syring
benefit mind easi ask v-go sale
rel lacklust past histor valerita use strategi
reach broad swath potenti prescrib approach turn
expens less effect hope compani turn
focus high-touch sale approach limit number
physician visit increas number visit target strategi
shown earli evid traction expect posit prescript
trend continu
addit believ vlrx could rel inexpens acquisit
target larg diabet compani look enter expand presenc
risk invest vlrx howev biggest concern
compani long-term fund requir investor wari
anticip share dilut warrant rel larg insid
ownership posit well potenti competit type
space think address risk vast market
plenti room new entrant believ manag need
commun clearli investor plan capit rais strategi
compet larger player
hard say investor decid reward vlrx strong
growth especi investor digest potenti warrant dilut
feel ultim vlrx keep grow model next
two year eventu share move higher
reason buy
convinc clinic benefit devic target
v-go conveni way dose insulin numer studi
shown patient use v-go experi better glucos control see
reduct compliant insulin therapi use less
insulin observ higher complianc insulin therapi like due v-
go design fact easi give bolus without other know
one insulin think compel design offer patient-friendli
option million patient well-control
one recent studi indic larg amount clinic data v-go
publish research social administr pharmaci compar patient
tri v-go return use insulin pen syring
patient stay v-go accord press releas summar
find month mean follow-up time patient stay v-go
larger reduct vs prescrib less
insulin units/day vs units/day accompani lower
medic cost chang measur
benefit key reason like valerita v-go technolog
view v-go featur capabl enabl posit clinic
result offer conveni all-in-on deliveri devic patient full
insulin need see two main benefit v-go patient usabl
small footprint simpl comfort design allow discreet
insulin deliveri patient place v-go push one
button deploy float needl start flow basal
insulin clinic literatur found patient type diabet
less like self-administ insulin away
home public that import bolu insulin
requir around meal easi deliv public set v-go
allow patient click two button deliv unit insulin
there need step away privat room bathroom
need sharp contain insulin pen/syring kit see v-go
remov hassl factor stay compliant insulin
therapi float needl may reduc pain pump
bump anoth posit see v-go design
devic commerci productat pointto offer
basal bolu insulin deliveri
conveni way self-administ bolu insulin like inhal v-go
product give patient abil dose basal
bolu insulin mean patient longer need purchas
long-act insulin dose basal insulin separ save time
money v-go fulfil basal insulin need continu deliv
small amount rapid-act insulin throughout day
reduc total dose insulin need increas uptak
manag note past doctor start put
patient v-go like becom frequent v-go prescrib
like observ clinic benefit repeat
across patient group instead see one patient experi
turnaround stori show traction high-touch
februari new manag team put place new sale
strategi includ dramat reduct salesforc headcount
rep rep well focu territori account high-insulin
volum prescrib describ time shift rep
visit doctor wide reach longer weekli visit target
group fewer doctor doctor take approach design
turn novic prescrib experienc v-go propon could observ
explain benefit devic
compani start implement new strategi first full
quarter plan place overal sale increas y/i even
though fewer half mani sale rep field increas
includ signific declin account longer focus
sale rep higher growth target account revenu dip
year-over-year basi first half due lower revenu
non-target account time rep manag
territori throughout report y/i growth target
account earli sign progress focus strategi
manag hire new sale rep target territori expand
averag rep rep begin
exhibit vlrx quarterli revenu
reduct headcount reach one-year anniversari
addit new sale rep first half stabil non-
target account v-go revenu began grow year-over-year basi
second half throughout first nine month vlrx grew
sale y/i nearli number sale rep show
growth sustain entir driven hire
exhibit show three stage strategi shift pre-turnaround year
implement stabl strong growth period
salesforc expans increas rep product
acceler growth near term
compani salesforc remain size rep
year time estim quarterli product per rep
increas almost valeritass manag
outlin plan expand salesforc
dont know exactli year hire take place
meaning increas revenu expect rep product dip near term
new hire lower averag recov sever quarter
although dont model dramat growth averag rep product
life model believ compani step toward hyper-focu
certain account leav upsid assumpt past
manag discuss experi frequent visit hand
physician translat larg shift mealtim insulin market share
doctor one pilot test second half saw v-go market
share increas among target doctor result led
valerita put hyper-focu group within territori april
believ earli result approach seen compani rapid
growth past year strategi translat time
account expect rep product continu increas
compani novemb earn call learn v-go
initi program run end intend
convert physician dedic prescrib give doctor chanc
put patient v-go expect see group
patient one two one-off patient benefit v-go therapi
doctor program becom regular prescrib think
worthwhil short-term invest though dont yet model
widespread impact eager see revenu reflect win
program becom regular part compani strategi
salesforc attrit alway concern small med-tech compani
especi share declin remain issu monitor
valerita note octob compani implement
induc plan stock award option grant employe
option grant follow novemb offer
outsid salesforc expect patient awar v-go increas
come quarter valerita discuss plan launch direct-to-consum
advertis potenti televis certain region dont anticip
major immedi uptick sale tv airtim think could
acceler increas rep product outyear
compani improv gross margin profil
rel low revenu level signific room
thank part low-cost natur v-go fact devic
electron part valerita abl report rel
high gross margin medic devic compani size gross margin
level increas fast pace
compani expect exit gross margin
estim revenu fourth quarter
impress consid med-tech compani
diabet sub-sector report significantli higher level revenu
achiev gross margin instanc neutral
first reach gross margin level second quarter
report quarterli revenu neutral hit
gross margin mark third quarter report
quarterli revenu rate yet report
gross margin accord analyst estim set reach
mileston fourth quarter expect report
estim revenu
expect valeritass gross margin continu increas healthi pace
alongsid rise revenu manag discuss long-term gross
margin goal model bp gross margin improv
year horizon model exit
provid upsid current revenu expect
valerita newli launch countri outsid unit
state yet forecast meaning intern revenu
compani sinc v-go sold distributor good
sens impact sale could becom
vlrx model assum minim ou revenu contribut
sinc correl
prescript fill level
achiev plan adjust outlook first coupl quarter
intern distributor sale result give us accur pictur
review histor consensu estim believ street model
littl impact intern revenu point
v-go prefil pipelin product h-patch platform
valeritass product pipelin includ v-go prefil v-go pre-
packag fill insulin cartridg includ detail v-go prefil
pipelin product section view meaning
patient adopt trend avail remov anoth step
patient routin may offer cost save
separ v-go reli upon hydraul approach dose basi
h-patch technolog believ platform potenti
use inject futur may give valerita anoth
sourc revenu drug deliveri partner variou pharmaceut
risk buy thesi
concern come signific dilut
valerita cash end septemb estim
would last second quarter compani
current burn novemb secondari equiti offer ad
coffer immedi anoth avail exercis
seri warrant addit seri warrant
believ compani well-financ horizon financi model
howev offer requir vlrx issu new share
possibl share via warrant exercis larg
number share rel share outstand end
septemb significantli limit upsid share price
opinion addit breath room around capit need lift
vlrx share outlook long term surpris recent
weak share price market digest dilut addit cash
necess unfortun market time volatil led mani
warrant requir bring capit valerita need grow
revenu extens off-set dilut
valerita small stand-alone compani field
domin larg well-fund healthcar compani
sell v-go devic valerita go establish insulin pen
player novo nordisk nvo rate sanofi sni rate
rate well indirectli compet well-known diabet
rate ypsome ypsn-swx rate includ
partnership like sfc fluidic jdrf although think valerita
increas v-go adopt penetr type popul note
compani direct sale rep small fraction sale
team larger healthcar compani command
prior insulin pump offer fail
type diabet popul repres massiv unmet need medic
technolog import note med-tech compani
face challeng insulin pump market
unilif corpor develop imperium insulin patch pump basal-
bolu deliveri launch devic target
popul howev earli unilif sold right imperium
underli wearabl inject platform soon compani
declar bankruptci asant snap insulin pump avail patient
mostli close asset acquir
bigfoot biomed case reason ceas oper seem
relat financi need rather issu product
clearli dont believ past compani closur mean valerita
succeed insulin pump fact compani growth rate
past year show corpor strategi gain traction recent
believ abbott freestyl libr cgm help bring wearabl medic
technolog diseas manag popul
mani compani continu discuss pipelin
product serv patient believ improv form insulin
deliveri like v-go penetr popul gradual
commerci strategi reli upon engag salesforc
interest patient recept physician
flip side valeritass turnaround high-touch strategi
underli revenu growth requir prescrib patient will spend
time energi learn v-go enthusiast product
salesforc risk isnt uniqu valerita rel small
salesforc crucial compani lose key top-perform sale
rep believ compani effort incentiv sale rep includ
option grant stock award help retain talent
exercis signific proport insid ownership
may concern investor
like small medic devic compani valerita yet profit
compani requir equiti debt fund past may requir
capit futur especi debt come due sinc
altern public offer valerita rais equiti
includ novemb seri warrant debt
half later convert prefer share anoth
proce expect novemb warrant exercis howev
fact eventu warrant exercis meaning dilut
compani share count may keep potenti investor bay account
full dilut novemb seri warrant
valuat
addit capit royalti group crg major sharehold
compani share outstand includ convert
prefer share novemb rais accord recent sec
file crg purchas share warrant novemb
offer maintain similar level ownership overal addit valerita
term loan crg crg statu creditor larg
sharehold mean compani continu good relationship firm
vlrx rate buy price target base month
revenu estim assum full share dilut view revenu multipl
conserv given compani strong revenu growth lack
regulatori clinic data risk mani compani grow trade
well revenu believ recent secondari offer
anoth avail warrant exercis remov near-
term financi overhang despit dilut make share
palat investor next quarter think vlrx share
trade around quarterli result updat sale penetr within
target territori meaning revenu contribut ou
distribut agreement longer term believ signific room
multipl expans compani continu execut high-touch
commerci strategi expand margin withstand upcom
quarterli updat revenu penetr salesforc addit
quarterli earn call manag typic offer metric growth rate
total new prescript target non-target account
well price trend sale rep hire expect vlrx share trade
reaction report revenu prescript growth trend commentari
sale rep product prescrib adopt
announc new ou distribut agreement recent
valerita offer v-go earli compani began
enter distribut agreement ou distributor part
strategi expand intern thu far valerita sign distributor
agreement itali australia new zealand austria germani slovakia
czech republ gulf cooper council member state
ntm inc ingnnot diabetestndmnot medicalwmginot factset data btig estimatespr ptpricemarket cap bev/salescagrev/gross profit
compani also work partner china regulatori process
countri earli august valerita announc launch v-go
new zealand first intern geographi v-go v-go also
avail australia itali news addit ou distribut
partnership could posit vlrx share particularli target
launch v-go sim v-go sim simpl insulin manag accessori
anticip launch summer sim make data v-go avail
patient via smartphon data along agreement
glooko data manag intend use improv diseas
manag give patient knowledg insulin
remain seen meaning product extens v-go
adopt vlrx share may trade around announc launch upon
updat patient adopt
competit entri type patch pump market high
volum innov technolog target type diabet market
time awar two competit launch horizon bolus-
devic acquir cequr calibra medic juli
slate us launch swatch patch pump becton
dickinson basal bolu insulin dose slate limit launch late
beyond compani like cellnovo bigfoot
biomed beta bionic may also competit offer
point vlrx share may react neg earli day
competit launch think long term larg type market poorli
penetr accommod multipl pump player
valeritass current target market focus patient type diabet
requir insulin compani estim approxim million us
patient type diabet use insulin million
patient well-control blood glucos level mean
could potenti benefit better complianc insulin therapi tweak
dosag time improv form deliveri
valerita report approxim prescript
fill year though dont know proport
prescript fill regular monthli user vs new occasion user
correl prescript fill everi month year clear
valerita bare scratch surfac term penetr
within target account sale rep spend time
prescrib manag note v-go enjoy roughli
market share even across target group varianc share
doctor write mealtim insulin prescript v-go
valerita intend spread prescrib behavior target
prescrib via higher focu strategi like initi program
estim sale rep gener approxim revenu
simplic sake revenu non-target account
doubl market share tripl share target
account would bring sale per rep effort combin
plan expans sale forc point fast growth rate
diabet market overview primer
pictur diabet treat
diabet chronic diseas known cure caus pancrea
either produc enough insulin bodi unabl use
insulin effect type diabet insulin product problem
type diabet bodi either unabl effect use insulin
pancrea produc enough case bodi
properli regul blood glucos level lead elev glucos
discuss detail diabet manag type overal goal
keep glucos level within specif rang glucos must maintain
certain level normal bodi produc insulin keep
concentr rang glucos level go rang
hyperglycemia left untreat extend period time long-term
complic develop heart diseas vascular diseas often lead
limb amput renal diseas eye diseas blind diabet often
administ insulin medic reduc glucos level attempt
keep within normal rang howev much insulin med
lower glucos normal rang hypoglycemia hypoglycemia
usual treat sugar juic candi sweet treat
result loss conscious death manag diabet constant
balanc act minim time spent hyperglycemia
mani data sourc avail diabet market one
comprehens overview size diabet popul estim
spend intern diabet feder idf diabet atla
compil data sever sourc world-wide summar key
point think relev purpos relat med-tech
product glucos monitor insulin pump
diabet one preval diseas estim global
preval million peopl known cure
continu grow multitud reason notabl lifestyl shift
includ sedentari habit poor diet total preval estim
rise million world-wide estim includ
diabet type ii gestat well undiagnos diabet
although magnitud popul display larg problem
diabet need segment relat med-tech
first focu primarili develop market europ part
asia diabet larg undiagnos and/or untreat much
emerg market exampl estim diabet popul
undiagnos north america caribbean compar
region like africa diabet undiagnos asia
half undiagnos addit level spend per capita
diabet treatment vari drastic countri spend
estim per year versu countri like india bare
spend despit home second largest diabet popul
second focu primarili popul primari user
dispos v-go insulin deliveri system describ
differ summari view
popul massiv opportun take time penetr
advanc medic technolog diabet today focus
also known juvenil diabet autoimmun diseas
bodi attack insulin-produc cell pancrea result bodi
unabl produc insulin without daili insulin inject lead
death usual diagnos adolesc activ manag
peopl diagnos live rel normal life
addit maintain healthi lifestyl term diet exercis
treatment requir two process monitor glucos deliv
insulin monitor patient need either test blood sugar
multipl time day blood glucos meter bgm use continu
glucos monitor cgm devic deliv insulin patient either
use insulin pen inject insulin wear insulin pump
difficult precis measur exact preval popul
preval studi typic distinguish
said rarer form repres diabet popul
unit state american diabet associ estim
preval alon million peopl adolesc
popul global idf estim million peopl age
new pediatric/adolesc patient diagnos year
common form diabet pancrea abl
produc insulin either produc enough bodi develop
resist essenti becom ineffect control glucos
level time insulin level becom insuffici result hyperglycemia
go undetect year diagnos patient even
diagnos receiv type manag requir
although argu patient would greatli
benefit pose signific burden medic system
complic lead cardiovascular diseas
blind kidney failur vascular diseas amput
complic avoid glucos level maintain often
time person diagnos alreadi develop least one
complic
unlik peopl requir daili insulin surviv
peopl diagnos basic told eat healthier exercis
possibl lose weight also sever medic help
stabil blood glucos level day oral medic
metformin gliclazid well analogu inhibitor
affect bodi digest food order reduc glucos level post
meal howev glucos level continu rise patient may
 alon estim million peopl
mani undiagnos particular interest current market glucos
monitor insulin therapi estim approxim million
patient insulin depend treat like
market opportun especi recent cgm technolog made
simpler monitor patient earlier and/or treat patient
insulin earlier diagnosi
discuss goal treat diabet keep glucos level
healthi rang insulin depend patient requir
either multipl fingerstick test per day bgm wear cgm
differ two like differ photo
video bgm give patient seri snapshot
inform direct happen cgm paint
full pictur continu line indic direct patient use cgm
gain maximum amount inform glucos level
abl catch hyperglycem hypoglycem event otherwis might
miss patient look discret point throughout day
major patient current test use fingerstick lanc
fingertip appli drop blood test strip glucos
sensor lanc glucos monitor readili avail pharmaci
estim number patient use fingerstick
cgm requir patient insert dispos sensor skin wear
transmitt sensor carri receiv display read
demand latest gener requir calibr
fingerstick dose insulin cgm becom preval
monitor diabet believ quickli achiev
market monitor market research firm expect cgm market
grow annual compound-annual-growth-rate next sever year
cgm adopt grown rapidli devic demonstr accuraci
rel easi use clinic benefit continu data
shown accuraci devic gaug mean absolut rel
differ mard score significantli improv year
devic move current dexcom
eversens comparison purpos singl
fingerstick mard score eas use
devic market today take minut set home
integr smartphon intuit interfac also integr
devic pump clinic benefit sever public
includ peer review publish data
well jdrf-fund trial shown time spent within healthi glucos
target rang reduc hemoglobin level signific improv
glucos control use cgm cgm may also great valu kid
elderli benefici parent caregiv also monitor
discuss two primari method deliv insulin
multipl daili inject mdi wear insulin pump exclud v-go
insulin pump primarili use manag
type insulin awar rapid-act short-act intermediate-act
long-act categor either basal bolu basal
typic intermedi long-act insulin background insulin
use stabil level day bolu typic short rapid-
act insulin use around mealtim manag increas glucos
level eat v-go use rapid-act insulin bolu
mdi routin dose insulin involv take basal dose insulin
non-meal time around time day take shot
bolu insulin whenev eat requir good amount plan
consider everi meal hassl inject
everi meal social stigma pop insulin kit social
set deter patient dose believ almost insulin-
depend patient use mdi insulin deliveri choic
tradit insulin pump requir patient wear devic carri
insulin bodi either infus set tube straight on-
bodi patch-pump pump deliv basal insulin throughout day
maintain glucos level deliv bolu patient direct
mealtim patient also abl increase/decreas basal dose
throughout day need monitor throughout day insulet
neutral key player insulin patch pump market estim
pump therapi us market penetr
penetr insulin-depend insulin pump market world-wide
estim sever compani industri sourc grow compound-annual-growth-rate
mid-upp singl digit market share taker grow double-digit rate
come decis deliv insulin pump mdi
sever pro con posit side pump discret
bolu dose perform meal time social set without
need take insulin kit view clear benefit v-go
insulin pump also allow easier monitor collect data
insulin use help patient parent doctor payor
expect possibl v-go sim multiday pump
easier set worri sever day dispos v-
go fill daili insulin depend patient prefer sever v-
go pump could fill ahead time simpler daili routin tradit
insulin pump intend popul allow user set
nighttim insulin dose wake need term glucos
level pediatr popul allow parent set monitor
children dose day around
neg side mani peopl might like idea
someth attach bodi may uncomfort could snag
throughout day skin irrit anoth concern around site due
adhes think may less issu daili v-go
adhes doesnt need last one day patient
may aspect fear around mechan failur feel
control use mdi lastli cost addit concern tradit
insulin pump expens insulin syringe/pen kit howev
insur coverag v-go cost daili mdi therapi
thing consid believ insulin pump better treatment
option though patient choic cost big factor
close loop artifici pancrea
artifici pancrea ap holi grail market devic
diabet year ap refer full connect
monitor glucos deliv insulin close system mean
littl input patient believ three
piec need come togeth monitor glucos deliveri
insulin softwar algorithm accur consist predict
glucos trend decid dose insulin technolog exist
insulin pump key leg stool softwar
believ one reason industri larg
tech presenc partner rate watson
partner verili numer stand-alone softwar
compani monitor pump continu crank data insulin
glucos believ tech compani best suit work larg
quantiti data develop appropri algorithm
medic devic compani form partnership reward
long term believ progress toward true ap continu
focu diabet commun compani investor alik
major maker insulin syring insulin pen needl
sharp dispos product dispos insulin
pump intend patient popul develop name
swatch pump expect three-day pump dose basal
bolu purpos use rapid-act insulin manag expect
put swatch equival cost level patient insulin pen therapi
accord latest commentari compani swatch slate
clear avail limit launch late would
repres direct competit v-go
juli cequr acquir fda-approv onetouch devic
calibra medic johnson johnson compani three-day pump
design deliv bolu insulinbut basaland expect
launch differ name purchas cequr
develop paq three-day basal-and-bolu insulin pump
fda clearanc diabet mine blog post time acquisit
report cequr still plan file paq fourth quarter
target launch
medtron diabet group offer wide varieti product includ
minim hybrid close loop system minim revel insulin pump
guardian connect cgm system guardian sensor well softwar
like ipro profession cgm evalut carelink sugar iq diabet
assist compani also sell infus set contournext link
blood glucos meter connect guardian sensor
pump automat dose insulin deliveri target rang
hybrid full ap user still need enter carb meal
adjust exercis launch june unit state
fall europ revenu total diabet group
billion estim grow billion y/i
abbott major maker blood glucos meter freestyl
brand name sell sever varieti includ freedom
precis avail counter price
inexpens abbott introduc freestyl libr europ
market flash gm sinc approv us
version approv fda septemb version
approv juli version real-tim alarm recent clear
europ libr last day requir zero calibr scan
glucos level swipe meter swipe
devic upload hour glucos data devic see libr
fill need bgm cgm provid sever benefit
cgm also less expens see sever benefit system name
cost eas discreet size roughli size silver dollar product
popular believ acceler penetr cgm-like
technolog patient popul third quarter
libr reach annual revenu run rate revenu
diabet care group billion revenu project
roch step back tradit bgm insulin pump market
unit state transfer us insulin pump custom
august howev compani remain activ diabet juli
roch tubeless micropump accu-chek solo receiv ce mark
compani also acquir digit diabet app mysugr june addit
roch distributor eversens implant cgm sever
market leader cgm latest offer cgm
dose claim fingerstick need dose insulin
calibr requir think plan enter insulin
deliveri busi believ focus remain leader
monitor reli partnership maintain exposur artifici
pancrea race say agnost develop long
use cgm form partnership pump
provid discuss except collabor
agreement verili healthcar arm googl develop
miniatur devic dxcm-verili product anticip launch
late compani also develop dispos glucos
record product use nearli anyon final august
acquir maker incontrol softwar
diabet manag platform allow cgm commun
insulin pump tandem diabetes-dexcom-typezero product slim
control-iq expect us summer revenu
consensu estim revenu repres
senseon implant cgm system eversens consist part
implant small sensor transmit app worn outsid bodi
implant receiv mobil phone implant done
endocrinologist offic version approv us
day eversens xl ce mark compani commerci product
europ us trial eversens xl expect start soon one-year
implant part compani product pipelin
glysen develop long-term implant cgm system eclips
expect stay bodi year longer consist part fulli
implant sensor extern receiv monitor compani
expect abl dramat reduc need calibr
state past demonstr less frequent fingerstick calibr
twice month compani complet us ou trial
reportedli show safeti feasibl seen recent public
updat fda ce mark timelin glysen also develop next-
gen two-year implant eclips expect smaller
sell omnipod insulin pump europ omnipod
self-contain on-bodi pump mean requir tube
devic carri bodi connect access point
via tube fulli dispos patient fill pod
enough insulin last day recent omnipod control
person diabet manag also contain freestyl
blood glucos meter bgm howev current limit us
launch omnipod dash expand full us roll-out earli
dash bluetooth-en touchscreen handheld compat
bgm contournext one ascensia longer integr
use bluetooth send glucos data dash data upload
variou data manag system includ provid glooko
also integr dexcom sensor omnipod technolog
develop omnipod horizon combin cgm insulin
pump enhanc smartphon control horizon anticip
commerci latter half addit compani work
rate incorpor humalog
could potenti open market larger dose need
total revenu us intern omnipod sale diabet
estim grow y/i
tandem sell slim insulin pump slim reservoir
insulin bolu pump design sleek intuit
color touchscreen interfac especi compar much
competit view august compani announc us
launch slim basal-iq technolog system incorpor
dexcom cgm sensor suspend insulin deliveri predict
technolog look ahead minut anticip low glucos tandem also
develop hybrid closed-loop system slim control-iq
use dexcom typezero algorithm allow
autom basal bolu insulin dose intend avoid
hypoglycemia hyperglycemia slim control-iq slate
launch us summer follow sport insulin
pump use smartphon control second half
tandem total revenu consensu
cellnovo compani base franc sell tubeless insulin patch
pump slim remov waterproof includ activ track
android pump control touchscreen integr bgm
bluetooth energy-en version ce mark last updat
compani plan file applic fda fall
cellnovo report system sold septemb cellnovo also
complet integr pump typezero algorithm earlier year
pois start three-day first-in-human trial artifici
pancrea technolog compani also collabor diabeloop
horizon artifici pancrea project cellnovo revenu
million consensu estim sale
nemaura medic uk-bas compani receiv ce mark design
earlier version sugarbeat product version
wristwatch-lik wire wearabl current product near
commerci daili dispos skin patch transmitt
recharg wireless product design offer non-invas glucos
measur everi five minut compani anticip ce mark
product end soft launch uk soon distributor
agreement qatar market launch also sign
patient fda trial slate complet first quarter
earli nemaura releas summari data subset
european studi show overal mard
believ nemaura plan pursu adjunct label
sugarbeat product could conceiv appeal peopl
diabet well consum tech applic view near-term
target pre-diabet patient popul particularli non-insulin
develop pogo automat blood glucos monitor system
essenti one-step bgm strip built-in dispos
cartridg devic patient place finger
button lanc test target market
somewher bgm cgm conveni bgm
costli cgm compani receiv fda clearanc april
rais million earli help launch system
bigfoot biomed uniqu compani acquir pump compani
asant shortli withdrawn ipo acquisit bigfoot
gain fda-approv pump compani larger aspir
commerci pump alon compani integr pump
abbott freestyl libr bluetooth-en artifici pancrea
system think bigfoot could start us trial artifici pancrea
system earli first half like similar number patient
requir trial mean
bigfoot ap system could avail us soon late
compani also develop bigfoot inject connect insulin pen offer
captur dose data enabl feedback loop expect
commerci artifici pancrea technolog bigfoot led
desborough bryan mazlish essenti hack devic
could upload daughter diabet data pebbl
smartwatch develop close loop system famili
beta bionic develop ilet system bionic pancrea technolog
capabl dose insulin glucagon algorithm use dose
licens boston univers american diabet
associ scientif session compani show strong data small
number patient patient achiev glucos control
goal standard care hit goal insulin-onli pump
achiev goal bihormon ilet technolog notabl
children hit goal bihormon technolog juli
beta bionic start home-us clinic trial ilet incorpor
use cgm eversens cgm pivot
trial ilet expect start compani target fda
approv insulin-onli version technolog
bihormon version
though directli devic softwar provid diabet manag
system play import role diabet treat
provid payor assess patient outcom believ
compat data previous mention
compani softwar algorithm drive adopt
develop market pump well enabl artifici pancrea
technolog novemb diabeloop announc hybrid closed-loop
system use dexcom cgm kaleido pump receiv
ce mark addit softwar algorithm play import role
interoper devic includ fit tracker provid
consolid platform view health trend
develop fda-approv afrezza inhal insulin
intend bolu insulin dose mealtim insulin cartridg avail
three load inhal use
find inhal deliveri mechan compel histor
inhal insulin met challeng marketplac mannkind
form market agreement sanofi sni cover
august compani miss expect less
product ship first month sanofi termin agreement
separ cover sanofi work exubera
first inhal insulin exubera subsequ pull two
year fail gain traction market believ part difficulti
launch inhal insulin fact fda recommend
doctor patient receiv pulmonari function test use
like gate item build sale recent afrezza inhal
undergon redesign result smaller sleeker devic mannkind
report afrezza sale first nine month
valerita medic technolog compani develop sell
v-go wearabl insulin deliveri devic use patient type
diabet v-go replac daili intend simplifi diseas
manag elimin need multipl daili inject insulin
fda clear v-go decemb devic sold
commerci unit state sinc
valerita form may revers merger valerita acquisit
corp incorpor compani call cleaner yoga inc valerita
hold inc incorpor delawar may enabl
compani begin trade otcqb along revers merger
compani issu privat placement million share unregist
common stock result altern public offer
march valerita announc revers stock split later
month compani uplist public
compani headquart bridgewat nj
manufactur facil marlborough contract manufactur
facil southern china
v-go daili dispos patch pump use deliv basal bolu
insulin patient type diabet small lightweight devic fill
rapid-act insulin either humalog novolog use ez fill tool
affix patient skin stomach back thigh back
arm use adhes back v-go avail
size depend amount insulin need patient may need
larger amount insulin day
small design lightweight
discreet altern multipl daili inject mdi insulin pump
rel comfort mm needl insert
skin flexibl so-cal float needl pivot reduc sensat
needl bodi push start button devic start deliveri
basal insulin bolu dose need patient push two
button deliv dose repeat need maximum
unit bolu insulin one day end wear period
patient releas needl peel v-go unlik patch pump
offer aim type patient popul v-go
see key advantag v-go compar mdi therapi first
conveni form factor abil dose insulin without take
suppli kit syring insulin pen remov stigma manag
type diabet mani patient may improv complianc
insulin regimen addit v-go simplifi insulin therapi allow
patient use one type rapid-act insulin fulfil basal
bolu need rapid-act insulin dose continu act basal
background dose mean patient longer need carri anoth type
insulin like intermediate-act long-act insulin serv basal
dose final describ v-go clinic data section patient
use v-go shown experi reduct level
use less insulin underscor v-go offer conveni
clinic benefit patient
v-go rel simpl design doesnt use electron compon
possibl insulin deliveri driven h-patch hydraul
technolog technolog use viscou pressur fluid push
rate-control flow restrictor flow rate fluid matter
fluid use push piston move insulin
reservoir deliv insulin continu rate basal purpos bolu
insulin deliv use hydraul approach bolu button
push v-go deliv insulin h-patch technolog could
appli type inject drug
exhibit detail h-patch technolog
much publish and/or present data v-go involv retrospect
analys emphas two main find v-go user experi reduc
level v-go user also use less insulin
enabl studi effect v-go wearabl insulin deliveri basal-
bolu therapi largest v-go studi date retrospect look
real-world patient type diabet level
subsequ start use v-go accord find present
venu like american diabet associ meet amcp
manag specialti pharmaci annual meet enabl reinforc
clinic econom benefit v-go reduc level less
enabl mean baselin reduc
percentag point three month v-go point seven month
patient mean total daili dose tdd insulin
baselin unit drop unit three month unit
seven month statist signific reduct level
observ across wide rang tdd insulin addit v-go
patient reach level patient abl
get level vs previou insulin therapi
hit target less vs previou
e-post present intern confer advanc
 treatment diabet show
retrospect v-go patient insulin pen user similar
baselin metricsth v-go group experienc larger mean reduct
level v-go vs pen use less insulin mean
units/day v-go vs mean units/day pen
accord compani press releas studi sever southern
california kaiser permanent clinic found v-go user mean
reduct units/day reduct mean insulin total
daili dose three month studi percentag
patient level fell v-go use
three month v-go
studi patient start use v-go
adjust insulin dose regimen accord physician
recommend base blood glucos read taken four time per day
poster dose chang occur first three
week studi four month patient reach
mean reduct percentag point
mean total daili dose insulin taken patient drop
significantli units/day units/day
may studi clinic benefit time associ
use v-go wearabl insulin deliveri devic adult patient diabet
retrospect analysi publish advanc therapi studi
reinforc clinic find sever prior studi month
mean reduct level reduct insulin
mean total daili dose units/day reduct
percentag patient concomit non-insulin glucose-low
medic baselin vs month what
month v-go cost diabet drug suppli decreas
mean per month patient previous mdi therapi
numer compani press releas cite present echo
find regard clinic benefit cost save associ v-go
v-go simpl insulin manag sim previous call v-go link
develop accessori v-go pull insulin dose data
devic send connect glucos meter smartphon tablet
rf/bluetooth-en offer intend give patient physician
better understand insulin use inform potenti adjust
v-go use diseas manag
april valerita sign three-year renew agreement glooko
allow v-go sim user use glooko digit diabet data
manag platform enhanc insight v-go data valerita
wrap beta test sim app work integr v-go
sim data glooko platform us contract manufactur produc
v-go sim
v-go sim slate us launch summer see
product help addit patient becom accustom
greater access data consum view nice-to-hav featur
may benefit engag patient physician
exhibit v-go sim left v-go prefil right
v-go prefil later product pipelin would allow patient skip
fill v-go insulin use think would remov yet
anoth hassl diseas manag improv complianc
patient would abl open new v-go prefil devic day put
ideal could reduc patient out-of-pocket cost month well
sinc would remov need buy insulin separ howev
potenti benefit depend price agreement insulin
partner valerita still must secur insulin partner prefil
develop complet addit eas use potenti
cost save v-go prefil expect extend platform patent life
exact time anticip v-go prefil launch unclear time
see three year away
accord valeritass latest file compani own us patent
foreign patent us foreign patent pend ip portfolio
cover key featur v-go h-patch drug deliveri technolog
includ float needl mini-ject technolog bolu button
hydraul driven fluid deliveri system dual-chamb design ez fill
tool design pre-fil cartridg pipelin product
patent expir ip cover float
needl bolu button reach expir first sever us
continu applic pend relat featur believ
valeritass ip cover uniqu aspect v-go h-patch technolog
enabl comfort discreet method accur insulin deliveri
competit come type patch pump market expect ip
portfolio discuss frequent advantag potenti
barrier new entrant
v-go larg avail patient via pharmaci channel accord
valerita v-go cover us commerci live
medicar part live though reimburs v-go rel
widespread compani continu broaden patient access instanc
second quarter cigna-healthspr part plan start
patient would typic pay two co-pay either tier v-go
rapid-act insulin compar mdi therapi patient would pay
three co-pay long-act insulin rapid-act insulin suppli
cost per month either approach similar though depend co-pay
level pen might bit cheaper accord past corpor present
patient might pay tier co-pay long-act insulin anoth
co-pay rapid-act insulin co-pay needl ad
monthli cost v-go patient might pay tier
co-pay v-go anoth tier co-pay rapid-act insulin
ad month sinc monthli spend almost
equival two therapi believ reimburs cost
barrier v-go adopt
also patient assist card avail help patient save co-
pay avail on-line v-go save card allow commerci
cover patient receiv v-go free first month never pay
refil
sale market manufactur
valerita current direct sale forc sale repres
deploy one target territori territori center around
major metropolitan center state compani yet cover
entir unit state part high-touch sale model rep focu
train clinician nurs v-go prepar patient
start v-go therapi sale strategi re-focus
priorit frequent touchpoint servic clinician led
increas market share among target account accord corpor
present v-go averag share account priorit valeritass direct
sale team increas end averag share
end estim near
v-go market model target high-volum prescrib insulin
direct-to-pati advertis intend attack adopt challeng
side provid educ support clinician encourag
prescrib v-go embolden patient ask clinician
v-go believ mix frequent offic visit clinic data updat
posit clinic outcom current v-go patient help increas
penetr among target account
besid territori servic direct sale forc also non-
target account alreadi prescrib v-go sale
strategi revamp account visit valerita sale rep
receiv servic insid sale team visit third-parti contractor
might expect prescript account decreas follow
shift sale strategi accord compani file number v-go
prescript target account increas y/i
prescript non-target account declin y/i howev
recent quarter declin total prescript written account
stabil earli sign growth new v-go start
addit despit slightli fewer prescript fill vs vs
revenu increas averag net sell price increas
account vlrx model increas
recent v-go sole avail within unit state august
valerita announc v-go launch new zealand mark
product intern debut sinc product also launch
australia itali compani work distributor sell v-go
outsid unit state current announc distributor relationship includ
movi spa itali amsl diabet australia nzm diabet new
zealand trust austria germani slovakia czech republ
well julphar gulf cooper council member state addit
valerita work intern contract research organ
chines regulatori process
valerita use contract manufactur southern china make v-go
may valerita complet altern public offer
million share sold
februari compani extend interest repay
period senior secur term loan agreement capit royalti
group later month half debt convert share
prefer stock time note payabl wca
capit partner iv convert prefer stock
march vlrx share went revers stock split
compani complet public offer uplist
januari valerita enter purchas agreement
capit commit buy worth share
month agreement termin replac second
agreement june worth share purchas month
approxim share sold two aspir
agreement addit compani agre at-the-market program
fbr januari share sold program
april valerita announc net proce public
offer share price
compani report cash total debt end
third quarter
proce share anoth come exercis
seri warrant equival share anoth anticip
exercis seri warrant equival share
john timberlak presid chief execut offic mr timberlak
spent almost year healthcar space valerita sinc
septemb start gener manag two year
becom chief commerci offic august ceo februari
valerita mr timberlak spent year sanofi includ
vice presid diabet market sanofi mr timberlak
certifi manag account certifi public account
manag deloitt touch llp mr
timberlak degre account missouri state
univers ms manag purdu univers mba
neoma busi school franc
erick lucera chief offic mr lucera valeritass cfo
sinc august come compani cfo treasur
secretari viventia decemb april mr
lucera vice presid corpor develop
held role titl sunshin heart inc march
decemb spent sever year investor includ role
intrepid capit partner independ invest
associ llc price waterhous co last posit investor
side eaton vanc manag vice presid
healthcar analyst februari novemb mr lucera also
current chairman audit committe mr
lucera cfa charter holder earn degre account
univers delawar also hold mba indiana univers
master scienc financ degre boston colleg certif
public harvard univers
matthew nguyen chief commerci offic mr nguyen
valerita sinc septemb hire vice presid
integr healthcar manag becam compani senior vice
presid commerci februari name chief
commerci offic decemb join valerita mr nguyen
new busi develop director janssen lp
work sanofi head health econom research
metabol new product market head analyt commerci
effect busi unit mr nguyen bs pharmaci
doctor pharmaci philadelophia colleg pharmaci
scienc also rutger univers finish fellowship
econom outcom research thoma jefferson
univers hospit janssen pharmaceut inc
joseph saldanha chief busi offic mr saldanha extens
experi diabet space chief busi offic
valerita sinc januari prior join compani vice
presid market busi develop mannkind corpor
mr saldanha gener manag julphar diabet gulf
pharmaceut industri januari may
work johnson johnson diabet focus busi
develop commerci lifescan anima product
mr saldanha work exubera aventis-pf
launch actonel us lantu intern sanofi earn
bachelor scienc degre drexel univers master scienc
degre univers pennsylvania
main competit v-go today insulin pen syring use
administ multipl daili inject insulin numer global
region maker insulin pen major manufactur includ sanofi
novo nordisk owen mumford accord consum guid
publish diabet forecast patient use insulin syring
avail sever differ manufactur includ
outsid insulin pen syring field differ medic
technolog compani develop insulin deliveri product type
popul includ devic previous known onetouch via
acquir cequr calibra medic mannkind afrezza becton
dickinson swatch insulet develop
cequr purchas onetouch via devic johnson johnson
calibra medic juli devic slate launch
renam worn three day use
deliv bolu insulin need differ v-go
deliv basal bolu dose insulin cequr also
develop paq three-day basal-and-bolu insulin pump
fda clearanc last reportedli slate
file fourth quarter target launch
rate sell afrezza inhal insulin
provid bolu dose around mealtim provid
rate develop swatch three-
day wearabl digit connect devic provid basal
bolu dose accord recent manag commentari
patient abl use rapid-act insulin swatch
basal bolu purpos expect enabl swatch therapi
cost insulin pen therapi anticip
clearanc limit launch late
neutral work rate
incorpor humalog could potenti
open market larger dose insulin need
may bit away option
may in-develop devic option yet
awar possibl competit entri present near-term
disrupt v-go sale seen competit anoth area
diabet marketcontinu glucos monitoringallow player benefit
increas awar believ could happen larg compani
like bring wearabl insulin deliveri devic type patient
addit devic option improv pharmaceut option
may impact competit landscap v-go long term
pancreat islet cell transplant may produc insulin diabet though type
like benefit first
vlrx revenu model base sale rep product assum
sizabl expans salesforc throughout hire
occur first quarter year influx new sale rep
model lower revenu per rep vs expect increas
steadili addit sale peopl gain experi outyear
continu project gradual increas product along increment
hire one two rep per quarter model assum sale rep
end shi expans manag discuss
increasingli slightli rep end salesforc
end use asp monthli v-go prescript
although increas net sell price past remain
conserv assum futur asp increas
fourth quarter estim revenu
forecast total revenu minim amount come
intern v-go sale look
revenu respect littl ou contribut
repres compound-annual-growth-rate growth rate see
achiev consid compani anticip y/i growth
plan salesforc expans revenu number correl
prescript prescript prescript
prescript
build vlrx gross margin profil model midpoint
guidanc fourth quarter manag expect exit
decemb gross margin forecast gross margin
like conserv
manag intern target seem feasibl given compani recent
histori gross margin increas
oper expens expect cost increas slightli
next year believ larger salesforc higher revenu drive
increas sg forecast sg expens revenu
horizon model believ revenu start outweigh
expens line around revenu level
incorpor meaning share count dilut model admit
dont exact idea seri seri warrant might
exercis instead work broad assumpt investor may
exercis seri warrant around nine-month deadlin howev
believ seri warrant might exercis gradual
five-year time-frame expect vlrx need
capit outyear model proce share dilut
exercis equal segment eight quarter
obvious perfect formula potenti acceler
delay share dilut vs assumpt
model averag cash burn go forward incorpor
addit share rais though depend time warrant
exercis vlrx like need addit capit late earli
model debt rais third quarter compani
vlrx incom good asset impair oper tax expens incom stock share net incom net incom analysisgross profit incom revenu oper oper btig estim compani report
vlrx revenu esal geographi unit y/i total patient prescript y/i v-go y/i asp y/i representativesunit per us sale rep growth revenue per us sale btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
